MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

490

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

August 5, 2027

Study Completion Date

December 31, 2027

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Colchicine 0.6 mg

Participants will take low-dose colchicine (0.6 mg once daily) in addition to ticagrelor maintenance therapy (90 mg twice daily), and discontinue aspirin the day after PCI. They will have an hs-CRP test 1 month after PCI. If the hs-CRP level is below 2 mg/L, colchicine will be discontinued 1 month after PCI. If it is 2 mg/L or higher, colchicine will be continued for 12 months after PCI.

Trial Locations (1)

13496

RECRUITING

CHA Bundang Medical Center, Seongnam-si

All Listed Sponsors
collaborator

Biotronik SE & Co. KG

INDUSTRY

lead

CHA University

OTHER